Driving Progress with Innovation in ADC Chemistry, Enhancing Patient Stratification in Clinical Trials, and Maximizing Manufacturing Efficiency to Advance ADCs Toward Standard-of-Care Oncology Therapies
Solidifying ADCs as Standard of Care Therapies by De-Risking Differentiated Payload MoAs Beyond Topo1, Elevating ADCs to Deliver Wider Impact in the Clinical Landscape & Adapting Manufacturing Efficiency for Novel & Cost-Effective ADCs
View Event
